Antimicrobial activity of LB10827, a new orally administered cephalosporin, tested againts Haemophilus influenzae, Moraxella catarrhalis, and Streptococcus pneumoniae

Abstract

A new orally administered cephalosporin, LB10827, was compared to 16 other anti-microbial agents tested against Streptococcus pneumoniae (520 strains), Haemophilus influenzae (302 strains) and Moraxella catarrhalis (188 strains) by reference broth microdilution methods. LB10827 (MIC90, 0.12 mg/L; highest MIC, 0.5 mg/L) was 8-16-fold more potent than cefdinir, cefpodoxime or cefuroxime when fested against S. pneumoniae. All Gram-negative strains were inhibited at ≤0.5 mg/L LB10827, which is an activity equal or superior to that of currently available and tested oral β-lactams. LB10827 appears to be a promising agent worthy of continued investigations both in vitro and in vivo.